inotuzumab ozogamicin (Besponsa)
inotuzumab ozogamicin is an FDA-licensed reference biologic from Wyeth Pharmaceuticals LLC. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2017
Reference approved
Reference product
Besponsa inotuzumab ozogamicin
Wyeth Pharmaceuticals LLC
- Approved
- Aug 17, 2017
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for inotuzumab ozogamicin, in chronological order.
Reference approval
Approval date of the reference inotuzumab ozogamicin product.
9 yr 1 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
in 4 yr 8 mo
Frequently asked questions
Are there biosimilars approved for inotuzumab ozogamicin (Besponsa)?
No 351(k) biosimilars or interchangeable biosimilars referencing inotuzumab ozogamicin are listed in the FDA Purple Book yet.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsThe list of FDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 & Inspection DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.